ISOLABS
LIVE

Serial Number

97491421

Owner

Isomorphic Labs Limited

Attorney

Lindsay B. Allen

Filing Date

Jul 6, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ISOLABS Trademark

Serial Number: 97491421

ISOLABS is a trademark filed by Isomorphic Labs Limited on July 6, 2022. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Isomorphic Labs Limited (12 trademarks)

280 Bishopsgate
London EC2M4RB , GB

Entity Type: 99

Trademark Details

Filing Date

July 6, 2022

Registration Date

Not Registered

Published for Opposition

May 9, 2023

Goods & Services

Downloadable computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for predicting protein structure, discovering pharmaceutical drugs, and developing pharmaceutical products; downloadable computer software applications for designing and developing artificial intelligence, information technology, deep learning technologies, machine learning technologies, and reinforcement learning technologies for predicting protein structure, discovering pharmaceutical drugs, and developing pharmaceutical products; downloadable computer software, computer programs and computer software algorithms for manipulating received or inputted data generated in a virtual space in connection with artificial intelligence methods, natural language processing, natural language understanding, dialog systems, voice and speech recognition and text to speech systems, natural language human-machine interfaces, and predictive assistance technologies; recorded computer programs using artificial intelligence, machine learning, deep learning, and reinforcement learning for software development in the fields of software for protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development

Software as a service (SAAS) services featuring software using artificial intelligence, machine learning, deep learning, and reinforcement learning for protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; advanced product research, design and development in the field of artificial intelligence; research and development in the fields of artificial intelligence, machine learning, deep learning, and reinforcement learning technologies; technology research in the field of artificial intelligence, machine learning, deep learning, and reinforcement learning for use in protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; computer software development in the fields of artificial intelligence, machine learning technologies, deep learning technologies, and reinforcement learning technologies, all for use in protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; software development consulting in the fields of artificial intelligence, machine learning technologies, deep learning technologies, and reinforcement learning technologies, all for use in protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; providing online, non-downloadable computer software platforms using artificial intelligence, machine learning, deep learning, and reinforcement learning for protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; development and testing of computing methods, computer software algorithms, computer software, and computer hardware; scientific, pharmaceutical, and medical research; scientific research in the field of computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for medical research, pharmaceutical research, protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; product research and development; medical, pharmaceutical, and scientific research in the field of protein structure prediction, pharmaceutical drug discovery, pharmaceutical product development, and computational biology; scientific and technological services, namely, scientific research and technological consulting, scientific research, development and design of computer software and technology in the fields of analytics and data mining, data analysis, data transformation, data visualization, statistical analysis, artificial intelligence, machine learning and virtual reality, science, chemistry, physics, biology, and scientific research; computer aided data analysis for scientific research purposes in the fields of artificial intelligence, machine learning, deep learning, reinforcement learning, building neural networks, data tree search, high performance computing, distributed computing, cloud computing, analytics and data mining, virtual reality, augmented reality, chemistry, physics, biology; computer modelling services; scientific services for the analysis of organic compounds; drug discovery services

Filing History

SOU TEAS EXTENSION RECEIVED
Jan 2, 2025 EEXT
TEAS PETITION TO AMEND BASIS RECEIVED
Jan 2, 2025 TPAD
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 2, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jul 2, 2024 EX2G
SOU EXTENSION 2 FILED
Jul 2, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jul 2, 2024 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 19, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 19, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 19, 2024 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 2, 2024 EXRA
SOU EXTENSION 1 GRANTED
Dec 29, 2023 EX1G
SOU EXTENSION 1 FILED
Dec 29, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 29, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 4, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 9, 2023 NPUB
PUBLISHED FOR OPPOSITION
May 9, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 19, 2023 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Apr 6, 2023 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Mar 31, 2023 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 25, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 25, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 25, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 25, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 25, 2023 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 24, 2023 GNFN
FINAL REFUSAL E-MAILED
Mar 24, 2023 GNFR
FINAL REFUSAL WRITTEN
Mar 24, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 22, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 21, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 21, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 21, 2022 GNRN
NON-FINAL ACTION E-MAILED
Sep 21, 2022 GNRT
NON-FINAL ACTION WRITTEN
Sep 21, 2022 CNRT
ASSIGNED TO EXAMINER
Sep 20, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 26, 2022 NWOS
NEW APPLICATION ENTERED
Jul 9, 2022 NWAP